Aimovig Pregnancy Exposure Registry
← catalyst calendarNCT06150781 · readout in 435 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
2,842estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-01-27 | actual | When the study began enrolling |
| Primary completion | 2027-10-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Intervention
- Drug: erenumab-aooe — also filed as Aimovig®
Primary outcome
what the primary-completion date above is the date OFNumber of Infants Experiencing Major Congenital Malformations
measured Up to 52 Weeks
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed